Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH
Explore linked clinical trials.2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-01 | NCT05958121 | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 1 | 2026-04-30 | NCT05359445 |